Cushing's Syndrome
Relacorilant improves cardiometabolic metrics for patients with Cushing’s syndrome
Among patients with endogenous hypercortisolism, relacorilant improved cardiometabolic parameters such as blood pressure, HbA1c and weight, according to results of a long-term extension study.
Top in endocrinology: New OTC glucose monitors; exposure to endocrine-disrupting chemicals
The FDA recently cleared two over-the-counter continuous glucose monitoring systems, one for adults with type 2 diabetes who do not use insulin and another for adults without diabetes who are looking to improve overall health and wellness.
Relacorilant lowers odds for loss of BP control for adults with Cushing’s syndrome
A selective cortisol modulator was linked to lower odds for loss of blood pressure control among adults with Cushing’s syndrome compared with placebo, according to topline results from a phase 3 trial.
Top in endocrinology: Low vitamin D can dampen vaccine response; HbA1c values questioned
Adults with vitamin D deficiency had lower COVID-19 vaccine antibody titers than adults with normal vitamin D levels 9 months after vaccination, according to a brief report in Endocrine.
Adults with Cushing’s syndrome report high burden of illness, despite ongoing treatment
Adults with endogenous Cushing’s syndrome reported that the condition moderately affects their quality of life and causes them to have symptoms about 16 days in a given month, according to findings published in Pituitary.
VIDEO: Pituitary research presented at ENDO 2023
CHICAGO —In this video exclusive, John Carmichael, MD, discusses some of the pituitary research presented at ENDO 2023, including treatments for Cushing’s syndrome and adipose effects following acromegaly cure.
Addressing glucocorticoid withdrawal syndrome in treatment of Cushing’s syndrome
To achieve optimal outcomes in Cushing’s syndrome, both clinicians and patients need to be prepared for the type and duration of symptoms that patients may experience during treatment and recovery.
Top in endocrinology: Gender-affirming hormone therapy; Cushing’s syndrome treatment
In a recent study, 98% of transgender adolescents who were prescribed gender-affirming hormone treatment after using pubertal blockers continued to use gender-affirming hormones in adulthood.
Cushing’s syndrome treatment maintains reductions in urinary free cortisol for 12 months
Most adults with Cushing’s syndrome receiving levoketoconazole twice daily maintained reductions in mean urinary free cortisol levels during a 12-month maintenance period, according to findings from the SONICS study extended evaluation.
VIDEO: New Cushing’s, acromegaly drug data prominent at ENDO annual meeting
ATLANTA — In this video exclusive, Maria Fleseriu, MD, FACE, reviews the pituitary research presented at the annual meeting of the Endocrine Society in Atlanta.